April 27, 2021 Acad, Gov/Utilities Licensing, IP, and Legal

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer

Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 2 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally... Read more

April 22, 2021 Clinical Research/Diagn. Environ, Ag./Food & Bev Licensing, IP, and Legal Life Science Tools M&A, Partnerships Product Launch

Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and Kartos Therapeutics, Inc. are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina’s comprehensive genomic profiling assay, TruSight™ Oncology 500 (TSO 500). This companion diagnostic for multiple hematologic indications will be the first to use TSO 500 with... Read more

April 16, 2021 Licensing, IP, and Legal Product Launch

New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis

85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity (NEDA) in open-label Phase IIIb ENSEMBLE study OCREVUS significantly slowed loss of brain tissue within T2 MRI lesions in primary progressive multiple sclerosis (PPMS) in post-hoc analysis of Phase III ORATORIO study OCREVUS-treated patients show highest adherence and persistence rates... Read more

April 14, 2021 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools

Bio-Techne Announces Licensing of Proprietary Antibody to Xencor for Therapeutic Development

MINNEAPOLIS, April 14, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced a license agreement for use of a proprietary Bio-Techne antibody by Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, for its therapeutic development pipeline. Bio-Techne is a global life sciences company providing... Read more

April 5, 2021 Licensing, IP, and Legal Liq. Handling & Robotics

Brooks to Participate in the 20th Annual Needham Virtual Healthcare Conference

CHELMSFORD, Mass., April 5, 2021 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 which includes a 40-minute webcast beginning at 12:45 p.m. ET.  The live webcast can be accessed through the Brooks investor relations website at www.brooks.investorroom.com/events.  A... Read more

March 29, 2021 Lab Top-10 Licensing, IP, and Legal Liq. Handling & Robotics

Horizon Discovery Extends Gene Modulation Portfolio with Industry First Synthetic Single Guide RNA and Patent Pending dCas9 Repressor for CRISPR Interference

CRISPRi Innovations Provide Expanded Experimental Options and Flexibility For Researchers Facilitating Disease & Drug Research WALTHAM, Mass.–(BUSINESS WIRE)–Mar. 29, 2021– Horizon Discovery, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its gene editing and modulation portfolio is expanding to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi). CRISPRi enables scientists... Read more

March 15, 2021 Licensing, IP, and Legal Liq. Handling & Robotics

Brooks to Participate in the KeyBanc Life Sciences & MedTech Investor Forum

CHELMSFORD, Mass., March 15, 2021 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 23, 2021 which includes a 35-minute webcast beginning at 1:15 p.m. ET.  The live webcast can be accessed through the Brooks investor relations website at www.brooks.investorroom.com/events. ... Read more

March 11, 2021 Environ, Ag./Food & Bev Licensing, IP, and Legal

Illumina and Harvard Pilgrim Health Care Real-World Evidence Study Demonstrates Cost-Effectiveness of Offering NIPT to All Pregnant Women

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN), along with researchers at the University of Colorado and Harvard Pilgrim Health Care (HPHC), reported study results evaluating the impact of an innovative risk-sharing agreement that opened insurance coverage of non-invasive prenatal testing (NIPT) for pregnant women under the age of 35. Through this partnership, thousands of women gained... Read more

March 9, 2021 Clinical Research/Diagn. Licensing, IP, and Legal

Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection

Kit expands Agilent’s product portfolio aimed at COVID-19 detection SANTA CLARA, Calif., March 09, 2021  Agilent Technologies Inc. (NYSE: A) today announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA. The CE-IVD mark is in accordance with the European Union In Vitro Diagnostic Directive 98/79/EC and... Read more

March 9, 2021 Atomic Spectroscopy Licensing, IP, and Legal

Luminex Corporation to Participate at the 2021 Barclays Global Healthcare Conference

Luminex® Corporation (NASDAQ: LMNX) develops, manufactures, and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. Luminex Corporation to Participate at the 2021 Barclays Global Healthcare Conference Mar 09, 2021 11:35 AM EST AUSTIN, Texas, March 9, 2021 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, Chairman, CEO & President, and... Read more